Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (SHA:600329)

China · Delayed Price · Currency is CNY

40.60

+0.64 (1.60%)

Apr 30, 2026, 3:00 PM CST

Revenue by Segment

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016
Chinese Patent Medicine	4.46B	5.66B	5.84B	5.65B	4.67B
Chinese Patent Medicine Growth	-21.14%	-3.07%	3.26%	21.04%	6.86%
Western Medicine	89.94M	1.19B	1.70B	1.78B	1.60B
Western Medicine Growth	-92.45%	-29.75%	-4.84%	11.74%	-2.99%
Others	366.23M	457.40M	673.08M	796.26M	626.90M
Others Growth	-19.93%	-32.04%	-15.47%	27.02%	8.97%
Total	4.92B	7.31B	8.21B	8.23B	6.89B
Total Growth	-32.70%	-10.96%	-0.31%	19.43%	4.59%

Revenue by Geography

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016
China	4.87B	7.27B	8.16B	8.20B	6.86B
China Growth	-33.02%	-10.92%	-0.44%	19.53%	4.36%
Overseas	47.80M	36.73M	44.88M	33.74M	33.91M
Overseas Growth	30.13%	-18.15%	33.00%	-0.48%	85.49%
Total	4.92B	7.31B	8.21B	8.23B	6.89B
Total Growth	-32.70%	-10.96%	-0.31%	19.43%	4.59%

Source: S&P Global Market Intelligence.